Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.

导出 LinkOut

翻译打印收藏纠错

作者： Amit,Bar-Or ^[1] ; Gian-Andrea,Thanei ^[2] ; Christopher,Harp ^[3] ; Corrado,Bernasconi ^[2] ; Ulrike,Bonati ^[2] ; Anne H,Cross ^[4] ; Saloumeh,Fischer ^[3] ; Laura,Gaetano ^[2] ; Stephen L,Hauser ^[5] ; Robert,Hendricks ^[3] ; Ludwig,Kappos ^[6] ; Jens,Kuhle ^[6] ; David,Leppert ^[6] ; Fabian,Model ^[2] ; Annette,Sauter ^[2] ; Harold,Koendgen ^[2] ; Xiaoming,Jia ^[3] ; Ann E,Herman ^[3]

作者单位： Center for Neuroinflammation and Experimental Therapeutics, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: amitbar@pennmedicine.upenn.edu. ^[1] F. Hoffmann-La Roche Ltd., Basel, Switzerland. ^[2] Genentech, Inc., South San Francisco, CA, USA. ^[3] Washington University School of Medicine, St Louis, MO, USA. ^[4] University of California, San Francisco, San Francisco, CA, USA. ^[5] Multiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel and University of Basel, Switzerland. ^[6]

关键词 Biomarker Disease progression Multiple sclerosis NfL Ocrelizumab

主题词人类(Humans);急性病(Acute Disease);疾病恶化(Disease Progression);中间丝(Intermediate Filaments);多发性硬化(Multiple Sclerosis);多发性硬化, 慢性进行性(Multiple Sclerosis, Chronic Progressive);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);复发(Recurrence)

DOI 10.1016/j.ebiom.2023.104662

PMID 37354600

发布时间 2023-07-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

EBioMedicine

2023年93卷

104662页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.

EBioMedicine

相似文献

EBioMedicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.

EBioMedicine

相似文献

EBioMedicine

相关期刊

检索历史清除